Safety, Tolerability, and Pharmacokinetics of Once-Monthly Oral Islatravir: A Phase 2a Study in Participants at Low Risk for Acquiring Human Immunodeficiency Virus Type 1.
Saved in:
| Title: | Safety, Tolerability, and Pharmacokinetics of Once-Monthly Oral Islatravir: A Phase 2a Study in Participants at Low Risk for Acquiring Human Immunodeficiency Virus Type 1. |
|---|---|
| Authors: | Hillier SL; Department of Obstetrics, Gynecology and Reproductive Sciences, Magee-Womens Research Institute and Foundation, Pittsburgh, Pennsylvania, USA.; Department of Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania, USA., Bekker LG; Department of Medicine, Desmond Tutu HIV Centre, Institute of Infectious Disease and Molecular Medicine, Faculty of Health Sciences, University of Cape Town, Cape Town, South Africa., Riddler SA; Department of Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania, USA., Hendrix CW; Department of Medicine (Clinical Pharmacology), The John Hopkins Hospital, Baltimore, Maryland, USA., Badal-Faesen S; Clinical HIV Research Unit, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa., Macdonald P; Department of Medicine, Desmond Tutu HIV Centre, Institute of Infectious Disease and Molecular Medicine, Faculty of Health Sciences, University of Cape Town, Cape Town, South Africa., Nair G; Department of Medicine, Desmond Tutu HIV Centre, Institute of Infectious Disease and Molecular Medicine, Faculty of Health Sciences, University of Cape Town, Cape Town, South Africa., Lombaard J; Research and Development, Josha Research, Bloemfontein, South Africa., Caraco Y; Clinical Pharmacology Unit, Division of Medicine, Hadassah Medical Center, Jerusalem, Israel., Peer A; Department of Oncology, Rambam Health Care Campus, Haifa, Israel., Patel M; MRL Research Laboratories, Merck & Co., Inc., Rahway, New Jersey, USA., Vargo R; MRL Research Laboratories, Merck & Co., Inc., Rahway, New Jersey, USA., Homony B; MRL Research Laboratories, Merck & Co., Inc., Rahway, New Jersey, USA., Nedrow K; MRL Research Laboratories, Merck & Co., Inc., Rahway, New Jersey, USA., Evans B; MRL Research Laboratories, Merck & Co., Inc., Rahway, New Jersey, USA., Wickremasingha P; MRL Research Laboratories, Merck & Co., Inc., Rahway, New Jersey, USA., Zhou YP; MRL Research Laboratories, Merck & Co., Inc., Rahway, New Jersey, USA., Teal V; MRL Research Laboratories, Merck & Co., Inc., Rahway, New Jersey, USA., Hwang P; MRL Research Laboratories, Merck & Co., Inc., Rahway, New Jersey, USA., McMullan C; MRL Research Laboratories, Merck & Co., Inc., Rahway, New Jersey, USA., Kaufman KD; MRL Research Laboratories, Merck & Co., Inc., Rahway, New Jersey, USA., Robertson MN; MRL Research Laboratories, Merck & Co., Inc., Rahway, New Jersey, USA., Plank RM; MRL Research Laboratories, Merck & Co., Inc., Rahway, New Jersey, USA. |
| Source: | The Journal of infectious diseases [J Infect Dis] 2025 Nov 14; Vol. 232 (5), pp. 1050-1060. |
| Publication Type: | Journal Article; Randomized Controlled Trial; Clinical Trial, Phase II |
| Journal Info: | Publisher: Oxford University Press Country of Publication: United States NLM ID: 0413675 Publication Model: Print Cited Medium: Internet ISSN: 1537-6613 (Electronic) Linking ISSN: 00221899 NLM ISO Abbreviation: J Infect Dis Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
Be the first to leave a comment!
